Core Viewpoint - Altimmune, Inc. is set to report its second quarter 2024 financial results on August 8, 2024, and will provide a business update during a conference call [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 8:30 am E.T. on August 8, 2024 [1] - The conference call will be accessible via a live webcast on Altimmune's Investor Relations website [1] - A replay of the conference call will be available on the Investor Relations website for up to three months after the event [1] Group 2: Company Overview - Altimmune is a clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapeutics [2] - The company is currently developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH [2]

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on behalf of long-term stockholders following a class action complaint that was filed against Altimmune on May 6, 2024 with a Class Period from December 1, 2023 to April 26, 2024. Our investigation concerns whether the board of directors of Altimmune have breached their fiduciary duties to the company. Altimmune ...

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, ...

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, ...

Industry Overview - Eli Lilly and Novo Nordisk dominate the weight-loss medicine market, driven by the popularity of their drugs Zepbound and Wegovy, respectively [1] - The weight-loss therapy market could reach $100 billion by 2030, indicating potential for new entrants to profit [1] Company Analysis: Altimmune - Altimmune's lead candidate, ALT-801, shows promise in achieving significant weight loss while minimizing muscle mass loss, which could appeal to specific demographics [3] - The company has over $182 million in cash, sufficient for approximately 24 months based on current operating expenses of $89 million [4] - Altimmune plans to meet with regulators in Q3 to discuss its upcoming phase 3 trial, positioning itself to compete with established players if results are favorable [4] Company Analysis: Terns Pharmaceuticals - Terns Pharmaceuticals is in the early stages of R&D with its only clinical-stage program, TERN-601, currently in phase 1 trials, with data expected in the second half of the year [5] - The company has $241 million in cash and equivalents, projected to last until 2026, with trailing-12-month operating expenses of approximately $104 million [7] - There is currently limited confidence in Terns' ability to compete with Eli Lilly or Novo Nordisk, as early-stage candidates face high failure rates in drug development [7][8]

Undervalued biotech stocks will always be relevant for the savvy investor.The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies. We’re seeing gene editing become more refined, with a growing appetite for advanced healthcare. On top of that, AI’s new role in drug discovery could take things up a notch or two for biotech players.However, the industry can be incredibly volatile: The stakes of clinical trials and FDA approvals are a make-or-bre ...

Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets. But what if you desire higher returns, even if it means more risk? Strategic investment in well-researched, riskier wild-card stocks can be the secret ingredient to amplifying your gains. Yes, there’s a chance of getting burned, but with careful selection and a dash of courage, you could just as easily win. So, ditch the boring and consider embracing the bold. Not all investors have th ...

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-sub ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as me ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as m ...